Clay T. Cramer

AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism

Stephen L. Pinkosky, Jeffrey C. Hanselman, Cheryl D. Bradshaw et al. · Journal of Lipid Research · 2012 · 225 citations · Full text

The Madin Darby Canine Kidney (MDCK) Epithelial Cell Monolayer as a Model Cellular Transport Barrier

Moo J. Cho, David P. Thompson, Clay T. Cramer et al. · Pharmaceutical Research · 1989 · 193 citations

ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK

Stephen L. Pinkosky, Richard J. Lister, Catherine Pawloski et al. · Journal of Lipid Research · 2013 · 84 citations · Full text

Lipid Peroxidation, Immunology, Immune Regulation +20

Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial

Narendra D. Lalwani, Jeffrey C. Hanselman, Diane MacDougall et al. · Journal of clinical lipidology · 2019 · 75 citations

Hypercholesterolemic Patients, Cardiovascular Disease, Medicine +6

Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome

Clay T. Cramer, Brian D. Goetz, Krista L. Hopson et al. · Journal of Lipid Research · 2004 · 70 citations · Full text